Oncology Medical News about thyroid cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Central lymph node dissection as a secondary procedure for papillary thyroid cancer
Surgery, 04/23/09

Alvarado R et al. - In a study to compare the clinical outcomes in pts with papillary thyroid cancer (PTC) who underwent central lymph node dissection (CLND) as a secondary event with those having initial CLND, it was shown that there is no additional morbidity when CLND is performed as a secondary procedure for pts with PTC. Secondary CLND should be performed in pts with proven central compartment metastatic disease after previous thyroidectomy and can be offered safely as a prophylactic procedure to pts at high risk for central lymph node metastasis when CLND has not been performed at initial primary operation for PTC.

Methods

A study of 193 pts who underwent CLND for PTC was undertaken.
Data gathered included pt demographics, number of lymph nodes excised, lymph node involvement, and incidence of postoperative complications.

Results

170 (M/F: 28/142) pts (Grp A) had a CLND as part of their primary surgical procedure while 23 (M/F: 10/13) pts (Grp B) underwent CLND as a secondary procedure (12 therapeutic/11 prophylactic procedures).
Mean number of lymph nodes sampled and percent involved in the 2 groups A and B were 9.2 vs 10.2 and 64% vs 61%, respectively.
Incidence of temporary hypocalcemia (12% vs 9%), permanent hypoparathyroidism (1.8% vs 0%), temporary recurrent laryngeal nerve (RLN) paresis (3% vs 4%), permanent RLN paresis (0.6% vs 0%), and wound infection (0.6% vs 4.3%) was comparable in groups A and B.

<< Previous
18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy...

Next >>
Serum bone turnover markers may be involved in the metastatic...